An official website of the United States government
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Trial Status: active
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy
with or without INCB161734 in participants with metastatic pancreatic ductal
adenocarcinoma (PDAC).
Inclusion Criteria
Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation
No prior systemic treatment in the metastatic setting
ECOG Performance status 0-1
Adequate organ function
Exclusion Criteria
Prior treatment with any KRAS inhibitor
Chronic or current active infection requiring systemic treatment within 1 week prior to the first dose of study drug
Known active CNS metastases Other protocol-defined Inclusion/Exclusion Criteria may apply.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07522073.
